2 days Ago
AstraZeneca PLC ( NASDAQ: AZN ) Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ET Company Participants Pascal Soriot - Chief Executive Officer Susan Galbraith - EVP, Oncology R&D Thomas Powles - Professor of Genitourinary Oncology; Director, Barts Cancer Centre Sunil Verma - SVP, Global Head, Oncology Franchise Dave Fredrickson - EVP, Oncology Business Matt Hellmann - VP, Early Oncology Development Cristian Massacesi - Chief Medical Officer, Chief Development Officer Oncology Melissa Scaltrisi - Head of Traditional Medicine Leora Horn - Global Clinical Strategy Head for Lung Conference Call Participants Tony Ryan - Macquarie Emily Field - Barclays Christopher Uhde – SEB Simon Baker - Redburn Sam Fazeli - Bloomberg Intelligence Alana Lelo - Guggenheim Richard Parks - BNP Paribas Exane Andrew Berens - Leerink Partners Etzer Darout - BMO Capital Markets Gonzalo Artiach - Danske Bank Mattias Haggblom - Handelsbanken James Gordon - JPMorgan Luisa Hector - Berenberg Rajan Sharma - Goldman Sachs Operator Welcome, ladies and gentlemen, to AstraZeneca's Investor Conference Call ESMO 2024. Before I hand over to AstraZeneca's management team, I'd like to read the safe harbor statement. The Company intends to utilize the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.
Participants on this call may make forward looking statements with respect to the operation and financial performance of AstraZeneca. Although we believe our expectations are based on reasonable assumptions, by their very nature, forward looking statements involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Any forward-looking statements made on this call reflect the knowledge and information available at the time of this call.
The Company undertakes no obligation to update forward looking statements. Please also carefully review the.
